Filing Details
- Accession Number:
- 0001209191-19-023950
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-08 16:11:00
- Reporting Period:
- 2019-04-04
- Accepted Time:
- 2019-04-08 16:11:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1293971 | Bluebird Bio Inc. | BLUE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1578696 | David Davidson | C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-04-04 | 6,360 | $5.50 | 37,976 | No | 4 | M | Direct | |
Common Stock | Disposition | 2019-04-04 | 2,623 | $159.47 | 35,353 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-04-04 | 2,704 | $160.22 | 32,649 | No | 4 | S | Direct | |
Common Stock | Disposition | 2019-04-04 | 1,033 | $161.14 | 31,616 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2019-04-04 | 6,360 | $0.00 | 6,360 | $5.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
6,690 | 2023-01-16 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019.
- The range in prices for the transaction reported on this line was $158.84 to $159.78. The average weighted price was $159.4691. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $159.88 to $160.75. The average weighted price was $160.2171. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $160.93 to $161.51. The average weighted price was $161.144. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.